arrow
M

Martin Regensburger

friedrich-alexander-universität erlangen-nürnberg
H指数:22
被引数:1,775

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Blood SOD1 Activity in ALS Patients Receiving Tofersen Treatment

ALS患者接受Tofersen治疗后的血液SOD1活性

2026-09-240
OAAI
Innate immune signaling as a potential pathomechanistic biomarker for distinct subtypes in amyotrophic lateral sclerosis

先天免疫信号通路作为不同肌萎缩侧索硬化症亚型的潜在病理机制生物标志物

2026-06-150
OAAI
Loss-of-function variants in the CAPN1 activator CD99L2 cause X-linked spastic ataxia

CAPN1激活因子CD99L2的功能缺失变异导致X连锁痉挛性共济失调

2026-02-140
OAAI
Compound Muscle Action Potential (CMAP) Amplitude Trajectories and Pattern in Adults with 5q-Spinal Muscular Atrophy Receiving Nusinersen Therapy: A Multicenter, Binational Observational Study

复合肌肉动作电位(CMAP)振幅轨迹和模式:接受nusinersen治疗的5q-脊髓性肌萎缩症成年患者的一项多中心、两国观察性研究

2025-11-010
OAAI
Deciphering brain organoid heterogeneity by identifying key quality determinants

通过识别关键质量决定因素来解析类脑器官异质性

2025-10-010
OA
Consensus on the clinical utility of digital mobility outcomes for personalized clinical decision support in parkinson’s disease

关于数字移动性结果在帕金森病个性化临床决策支持中临床应用价值的共识

2025-09-180
OAAI
Targeted Proteomics upon Treatment with Tofersen Identifies Novel Response Markers for Superoxide Dismutase 1-Linked Amyotrophic Lateral Sclerosis

靶向蛋白质组学在Tofersen治疗中发现与超氧化物歧化酶1相关的肌萎缩侧索硬化症的新型应答标志物

2025-08-090
OAAI
Clinical characterization of common pathogenic variants of SOD1-ALS in Germany (2024) 271:6667-6679)

德国SOD1-ALS常见致病变异的临床特征分析 (2024) 271:6667-6679)

2025-03-080
OA
Tofersen decreases neurofilament levels supporting the pathogenesis of the SOD1 p.D91A variant in amyotrophic lateral sclerosis patients

Tofersen降低肌萎缩性侧索硬化症患者中支持SOD1 p.D91A变体发病机制的神经丝水平

2024-07-256
OAAI
Patients' and caregivers' perception of multidimensional and palliative care in amyotrophic lateral sclerosis - protocol of a German multicentre study

患者和护理人员对肌萎缩性侧索硬化症的多维和姑息治疗的看法-德国多中心研究的协议

2024-07-041
OAAI
Activation and Purification of ß-Glucocerebrosidase by Exploiting its Transporter LIMP-2-Implications for Novel Treatment Strategies in Gaucher's and Parkinson's Disease

通过利用其转运蛋白LIMP-2激活和纯化 β-葡糖脑苷脂酶-对戈谢病和帕金森氏病新治疗策略的影响

2024-04-261
OAAI